Literature DB >> 23965900

Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity.

Aurélien Marabelle1, Holbrook Kohrt, Ronald Levy.   

Abstract

Systemic administration of the checkpoint blockade antibody anti-CTLA4 results in severe autoimmune toxicity, limiting its clinical efficacy. Fransen and colleagues show here that peritumoral delivery of low doses of this immunomodulatory drug can trigger a systemic antitumor immune response while preventing the toxicity against other organs.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23965900      PMCID： PMC3817012          DOI： 10.1158/1078-0432.CCR-13-1923

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

1.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

Review 2.  Cancer immunotherapy comes of age.

Authors:  Suzanne L Topalian; George J Weiner; Drew M Pardoll
Journal:  J Clin Oncol       Date:  2011-10-31       Impact factor: 44.544

Review 3.  Cancer immunotherapy comes of age.

Authors:  Ira Mellman; George Coukos; Glenn Dranoff
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.

Authors:  Mark J Selby; John J Engelhardt; Michael Quigley; Karla A Henning; Timothy Chen; Mohan Srinivasan; Alan J Korman
Journal:  Cancer Immunol Res       Date:  2013-04-07       Impact factor: 11.151

6.  Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity.

Authors:  Andrew D Simmons; Marina Moskalenko; Jennifer Creson; Jianmin Fang; Saili Yi; Melinda J VanRoey; James P Allison; Karin Jooss
Journal:  Cancer Immunol Immunother       Date:  2008-01-31       Impact factor: 6.968

7.  CTLA-4 control over Foxp3+ regulatory T cell function.

Authors:  Kajsa Wing; Yasushi Onishi; Paz Prieto-Martin; Tomoyuki Yamaguchi; Makoto Miyara; Zoltan Fehervari; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2008-10-10       Impact factor: 47.728

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects.

Authors:  Marieke F Fransen; Tetje C van der Sluis; Ferry Ossendorp; Ramon Arens; Cornelis J M Melief
Journal:  Clin Cancer Res       Date:  2013-06-20       Impact factor: 12.531

Review 10.  Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.

Authors:  Sergio A Quezada; Karl S Peggs; Tyler R Simpson; James P Allison
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988
View more
  29 in total

1.  Naloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responses.

Authors:  Sima Velashjerdi Farahani; Mohammad Reza Aghasadeghi; Arash Memarnejadian; Sobhan Faezi; Zahra Shahosseini; Mehdi Mahdavi
Journal:  Pathog Glob Health       Date:  2016-04-13       Impact factor: 2.894

2.  ImmTAC/Anti-PD-1 antibody combination to enhance killing of cancer cells by reversing regulatory T-cell-mediated immunosuppression.

Authors:  Huanling Zhang; Yanyan Li; Xiaoping Liu; Zhaoduan Liang; Mengyong Yan; Qiang Liu; Anan Chen; Yifeng Bao; Chengzhi Zhou; Shiyue Li; Cassian Yee; Yi Li
Journal:  Immunology       Date:  2018-06-14       Impact factor: 7.397

3.  Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity.

Authors:  Yongkui Li; Min Fang; Jian Zhang; Jian Wang; Yu Song; Jie Shi; Wei Li; Gang Wu; Jinghua Ren; Zheng Wang; Weiping Zou; Lin Wang
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

4.  Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies.

Authors:  Min Dai; Yuen Yee Yip; Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  Clin Cancer Res       Date:  2014-08-20       Impact factor: 12.531

Review 5.  Trial watch: Immune checkpoint blockers for cancer therapy.

Authors:  Claire Vanpouille-Box; Claire Lhuillier; Lucillia Bezu; Fernando Aranda; Takahiro Yamazaki; Oliver Kepp; Jitka Fucikova; Radek Spisek; Sandra Demaria; Silvia C Formenti; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-31       Impact factor: 8.110

Review 6.  Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Authors:  Mariona Cabo; Rienk Offringa; Laurence Zitvogel; Guido Kroemer; Aura Muntasell; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-30       Impact factor: 8.110

Review 7.  Advances in engineering local drug delivery systems for cancer immunotherapy.

Authors:  Peter Abdou; Zejun Wang; Qian Chen; Amanda Chan; Daojia R Zhou; Vivienne Gunadhi; Zhen Gu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-04-07

8.  Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes.

Authors:  Lucas A Horn; Tiha M Long; Ryan Atkinson; Virginia Clements; Suzanne Ostrand-Rosenberg
Journal:  Cancer Immunol Res       Date:  2017-11-09       Impact factor: 11.151

9.  Modeling multi-needle injection into solid tumor.

Authors:  Vladimir Subbotin; Gennady Fiksel
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

Review 10.  Updates on immunotherapy for colorectal cancer.

Authors:  Aparna Kalyan; Sheetal Kircher; Hiral Shah; Mary Mulcahy; Al Benson
Journal:  J Gastrointest Oncol       Date:  2018-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.